Recursion Pharmaceuticals, Inc.
RXRX
$4.45
$0.133.01%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.18M | 19.22M | 14.75M | 4.55M | 26.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.18M | 19.22M | 14.75M | 4.55M | 26.08M |
| Cost of Revenue | 135.75M | 148.80M | 151.46M | 111.13M | 86.68M |
| Gross Profit | -130.57M | -129.57M | -136.72M | -106.58M | -60.60M |
| SG&A Expenses | 41.63M | 46.65M | 54.65M | 77.29M | 37.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 177.38M | 195.45M | 206.11M | 188.42M | 124.44M |
| Operating Income | -172.20M | -176.23M | -191.37M | -183.88M | -98.35M |
| Income Before Tax | -162.25M | -171.90M | -202.65M | -178.90M | -95.68M |
| Income Tax Expenses | 3.00K | -- | -158.00K | 7.00K | 167.00K |
| Earnings from Continuing Operations | -162.25M | -171.90M | -202.49M | -178.91M | -95.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -162.25M | -171.90M | -202.49M | -178.91M | -95.84M |
| EBIT | -172.20M | -176.23M | -191.37M | -183.88M | -98.35M |
| EBITDA | -151.16M | -152.38M | -172.04M | -170.93M | -91.16M |
| EPS Basic | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 |
| Normalized Basic EPS | -0.23 | -0.26 | -0.31 | -0.33 | -0.21 |
| EPS Diluted | -0.36 | -0.41 | -0.50 | -0.54 | -0.34 |
| Normalized Diluted EPS | -0.23 | -0.26 | -0.31 | -0.33 | -0.21 |
| Average Basic Shares Outstanding | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M |
| Average Diluted Shares Outstanding | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |